GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Preferred Stock

Apollon Formularies (AQSE:APOL) Preferred Stock : £0.00 Mil (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Apollon Formularies's preferred stock for the quarter that ended in Jun. 2023 was £0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Apollon Formularies's Enterprise Value for the quarter that ended in Jun. 2023 was £1.30 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Apollon Formularies's Book Value per Share for the quarter that ended in Jun. 2023 was £0.00.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Apollon Formularies's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was £-0.00.


Apollon Formularies Preferred Stock Historical Data

The historical data trend for Apollon Formularies's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Preferred Stock Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Apollon Formularies Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Apollon Formularies  (AQSE:APOL) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Apollon Formularies's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Apollon Formularies's Book Value per Share for the quarter that ended in Jun. 2023 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Apollon Formularies's Earnings per Share (Diluted) (EPS) for the six months ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies Preferred Stock Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

FPA Capital Fund Finds Only 2 Stocks Matching Their Criteria in Q1

By Holly LaFon Holly LaFon 04-10-2013

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

Apollo Group: This Unloved Company Is Significantly Undervalued

By Matthew Dow Matthew Dow 05-09-2013

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015